Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 10 (1996), Issue 7, Pages 451-459

NSAID Gastroenteropathy: Past, Present and Future

John L Wallace

Intestinal Disease Research Unit, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

Received 11 October 1995; Revised 5 February 1996

Copyright © 1996 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) in the gastrointestinal tract continues to be a major limitation to their use in the treatment of inflammatory disorders. Better understanding of the pathogenesis of NSAID enteropathy has facilitated the development of novel NSAIDs that spare the gastrointestinal tract. In particular, identification and characterization of the inducible form of prostaglandin synthase has led to the design of novel NSAIDs that specifically target that enzyme. The pathogenesis of NSAID gastroenteropathy is reviewed, as are the strategies that have been used in the past and are used now to develop NSAIDs that spare the gastrointestinal tract. Also reviewed are the strategies being employed to achieve this goal in the future.